Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate vs Guanfacine for ADHD in Young Children
NCT07300956Phase 4Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Feb 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methylphenidate hydrochloride extended-release chewable tablet, guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Cincinnati Children's Hospital Medical Center. Started Feb 2026; status: recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tabletguanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07300956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300956.